A multicentric, non-randomized, open label, non-comparative, active post marketing surveillance (PMS) study to evaluate the safety and efficacy of Sinarest Oral Drops in infants of common cold.

Sinarest Oral Drops is a fixed dose combination of Paracetamol 125 mg, Phenylephrine hydrochloride 2.5 mg and Chlorpheniramine maleate 1 mg per ml which is indicated for the treatment of common cold. The rationale behind this ‘Active Post-Marketing Surveillance study’ is to document the efficacy and safety of Sinarest Oral drops for the treatment of common cold in infants. common cold of viral origin is a self-limiting disease which usually takes up to 10 days to cure by itself. Most of the patients suffer from common cold is due to viral infection of page upper respiratory tract. According to the guidelines of DPHHS and Cochrane review combination of analgesic, antihistaminic and decongestant medication can be used for the treatment of common cold. Taking this into consideration we have proposed Active Post-Marketing Surveillance study of Sinarest Oral Drops in infants of common cold.